Table 3. Genotype and allele frequencies of the P2RX7 1513 A/C polymorphism in controls and in women with CSCC and those with HPV-16 positive CSCC*.
Controls (N = 1619) |
CSCC (N = 507) |
HPV-16 positive CSCC (N = 240) |
CSCC | HPV-16 positive CSCC | |||
---|---|---|---|---|---|---|---|
n (%) | n (%) | n (%) | P value (χ) | OR (95% CI) | P value (χ) | OR (95% CI) | |
Genotype | 0.77 (0.54) | 0.48 (1.47) | |||||
A/A | 944 (58.3) | 304 (60.0) | 146 (60.8) | 1.07 (0.87-1.31) | 1.11 (0.84-1.47) | ||
A/C | 578 (35.7) | 172 (33.9) | 84 (35.0) | 0.92 (0.75-1.14) | 0.97 (0.73-1.29) | ||
C/C | 97 (6.0) | 31 (6.1) | 10 (4.2) | 1.02 (0.67-1.55) | 0.68 (0.35-1.33) | ||
Allele | 0.62 (0.25) | 0.30 (1.10) | |||||
A | 2466 (76.2) | 780 (76.9) | 376 (78.3) | 1.04 (0.88-1.23) | 1.13 (0.90-1.43) | ||
C | 772 (23.8) | 234 (23.1) | 104 (21.7) | 0.96 (0.81-1.13) | 0.88 (0.70-1.11) |
* CSCC = cervical squamous cell carcinoma; HPV = human papillomavirus; OR = odds ratio; CI = confidence interval.